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Abstract  
Thrombosis is a well-known side effect associated with Acute Lymphoblastic 
Leukemia (ALL) treatment leading to significant morbidity rates. Thrombosis 
occurrence in ALL patients seems to be due to the interaction between the disease, 
the therapy and the possible inherited genetic defects affecting the hemostatic 
balance. In this study we aimed to assess the prevalence of prothrombotic defects- 
FV Leiden, MTHFR (Methylene Tetra Hydrofolate Reductase enzyme) C677T & 
prothrombin (PT) G20210A mutations in Egyptian pediatric ALL patients and its 
impact on the risk of thrombosis onset as well as to evaluate the impact of the 
presence of single versus multiple prothrombotic mutations on thrombosis. Sixty 
three pediatric ALL patients with thrombotic event treated with ALL protocol 
adopted from SJCRH (Saint Jude Cancer Research Hospital) study XV at the 
Children’s Cancer Hospital in Egypt (CCHE) and 63 matched ALL control patients 
were enrolled in the study. Restriction fragment polymorphism technique was used 
to assess the prevalence of the FV Leiden and MTHFR C677T while Allele specific 
PCR was used for Prothrombin G20210A. Our results showed that MTHFR C677T 
prevalence between the ALL patients with and without thrombosis was 65% and 
38.1% respectively p value = 0.002. The FV Leiden prevalence between the ALL 
patients with and without thrombosis was 17.5% and 15.9 % respectively p value= 
0.81. While the prothrombin G20210A prevalence was 3.2% in both groups. In 
addition, patients who were older than 10 years or on SR/HR treatment protocol or in 
induction treatment phase were also at high risk of thrombosis. The presence of 
MTHFR C677T polymorphism can increase the risk of thrombosis 3 folds more than 
those patients who didn’t have the polymorphism, while FV Leiden and PT 
G20210A didn’t affect the thrombosis risk. Having more than one mutation didn’t 
show a significant effect on increasing the risk of thrombus incidence (p= 0.087). We 
concluded that MTHFR C677T is important risk factor for thrombosis in Egyptian 
pediatric ALL patients. These results may help in the prediction of the thrombosis 
susceptibility for ALL patients and a prophylaxis therapy may be considered before 
having the thrombosis. To the best of our knowledge these findings regarding the 
thrombosis risk factors in Egyptian pediatric ALL patients are first to be reported. 
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1. Review of Literature 
1.1 Acute Lymphoblastic Leukemia (ALL) 
1.1.1 Incidence and Epidemiology 
Acute Lymphoblastic Leukemia represent about 81% of pediatric leukemias 
(Woo, Alberti, & Tirado, 2014). It is the most common cancer in pediatric patients 
representing 25% of cancer diagnosed in pediatrics. ALL outcome is 90 % 5 years 
overall survival which is very high rate of survival among different types of cancer 
(Pui et al., 2013). The incidence of ALL in the United States is 35-40 new 
case/million each year. There is a gradual increase in ALL incidence in the previous 
25 years (Howlader et al., 2013). 
At National Cancer Institute (NCI), Egypt, ALL constitutes 19.6% of all 
childhood malignancies (Elattar et al., 2005), while the percentage of ALL cases 
treated in Children’s Cancer Hospital of Egypt (CCHE) in the period between 2007- 
2012 was reported as 20% (1305/6240) of all pediatric cancer patients (CCHE 57357 
Registry, 2012). There is a sharp increase in ALL incidences in age 2-3 years about 
90 new case/million each year worldwide. This rate decreases to 30 case/million per 
year by age 8 years. This high incidence of ALL among 2-3 years aged patients is 4 to 
5 folds greater than that of infants and 10 years or older aged children (Howlader et 
al., 2013). The incidence of ALL among white children is higher than that in black 
children. There is about three-fold increase in ALL incidences in 2 - 3 years aged 
white children than in black children. There is also a slight male predominance in all 
age groups (Howlader et al., 2013).  
1.1.2 Risk Factors for Developing ALL 
There are varieties of risk factors associated with increased ALL risk; these 
include X-rays exposure during prenatal stage, exposure to pesticides and ionizing 
radiations. In addition, ALL occurs with higher frequency in patients with Bloom 
syndrome, neurofibromatosis type I, ataxia-telangiectasia and Down syndrome. For 
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example, Down syndrome patients have a 20 fold increase in risk of ALL (Onciu, 
2009).  
On the other hand, there are factors with limited evidence to be a risk factor 
for ALL. Few studies suggest a higher risk (1.5 fold) in case of paternal smoking 
before pregnancy. Although some studies have reported increase in the ALL risk for 
children who live near high voltage; other studies reported no risk association. In 
addition to that few studies were done on the meat consumption in diet and showed 
association with the increase in risk (Blot et al., 1999; Howlader et al., 2013). 
1.1.3 Pathogenesis 
ALL originates in the bone marrow from either the T or B lymphoblasts 
(Figure 1). About 85% of pediatric ALL is B cell origin. The B cell origin ALL is 
classified into several subtypes: pre-B ALL, common ALL and pro-B ALL. On the 
other hand, T cell ALL represents 15% of pediatric ALL patients. Although T cell 
ALL patients are characterized by resistance to chemotherapy in comparison with the 
B cell ALL patients, the outcome of the ALL T cell approaches the B cell using risk 
adapted therapy in many study groups (Pieters & Carroll, 2010).  
Risk adapted therapy is therapy modification done according to the patient 
predicted risk for relapse. Patients who have high risk criteria receive aggressive 
therapy to prevent recurrence of the disease. While patients with good prognosis 
receive effective therapy with fewer side effects and at the same time less aggressive 
than that received by high risk (HR) patients. The factors used for the patients 
stratification into different treatment arms are clinical and biological factors (Pieters 
& Carroll, 2010).  
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Image adopted from http://www.cancer.gov/ 
Figure 1: A diagram showing the normal pathway for the differentiation of 
blood stem cell. In normal healthy child, the Bone marrow produce immature cells called 
blood stem cells, it can differentiate to either  a lymphoid stem cell or a myeloid stem cell. 
Myeloid stem cell differentiates into one of three blood cells which are; red blood cells, 
platelets and white blood cells. While lymphoid stem cell can differentiate into one of three 
types of white blood cells which are: B lymphocytes, T lymphocytes and Natural killer cells. 
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1.1.4 Clinical Presentation and Patients’ Outcome 
Acute Lymphoblastic Leukemia is a bone marrow disease. The onset of ALL 
is acute in most of the cases, although there are few cases that may evolve over 
several months. Doctors can suspect ALL when there are symptoms of pancytopenia 
(bone marrow failure). The most Common ALL signs and symptoms include bone 
pain, pallor, bleeding, easy bruising and fatigue. Signs of extra medullary 
involvement may appear in signs of intracranial pressure increase including headache. 
In addition, physical examination may show hepato-splenomegaly and lymph-
adenopathy (Woo et al., 2014). Laboratory abnormalities may include hyper 
leukocytosis, thrombocytopenia, leucopenia or neutropenia. Hyperleukocytosis 
appears in 15% of pediatric ALL patients. Another important laboratory abnormality 
is hyperuricemia that can result from tumor lysis (Onciu et al., 2009). 
The pediatric ALL prognosis has improved over the last decades, where 
therapy is adapted according to the patient’s level of relapse risk (low, standard and 
high risk groups) and the patient’s response to chemotherapy. In addition, the 
continuous appearance of new chemotherapeutic agents had a great role in improving 
the outcome. The pediatric ALL patients’ outcome has dramatically increased from 
10% in 1960 to a current 90% in many developed countries (Figure 2). The precise 
risk assessment, improved supportive care and the optimal use of chemotherapeutic 
agent have improved the 5 years disease free survival and the 5 years overall survival 
rates to more than 85% and 90 % respectively in several treatment protocols (Pui et 
al., 2013). 
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         Image adopted from doi:10.1053/j.seminhematol.2013.06.007. 
Figure 2: Survival assessed by Kaplan Mayer analysis for 2852 newly diagnosed 
pediatric ALL patients’ in St. Jude children cancer hospital from 1962 to 2007.  
During this time period, the patients have been treated by 15 different consecutive treatment 
plans. Ten year free survival rates are shown in the above curve. The results show a drastic 
improvement in patient outcome from 11.1% in the 1960’s to 91.1% in the early 20th 
century. 
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1.2 Treatment 
The ALL protocols of treatment consist of 3 main phases: induction of 
remission, consolidation phase and maintenance or continuation phase. The typical 
duration of the treatment is 2-3 years, according to which protocol is used. The goal 
of the induction stage is to induce remission and restore the normal blood cell 
production in bone marrow while the goal of the consolidation and the maintenance 
phases are to eliminate residual disease and maintain the patient in remission. In 
addition, chemotherapy can be injected intrathecally for central nervous system 
(CNS) prophylaxis or treatment from the disease. There are different types of 
antileukemic agents that are used for ALL treatment such as methotrexate, 6-
mercaptopurine, l-asparaginase, vincristine and glucocorticoids (Pieters & Carroll, 
2010).
 
1.2.1 Asparaginase 
In 1953, it was noted by Kidd that the serum of guinea pig has an antileukemic 
effect in mice. Then it was discovered that the reason of the antileukemic effect was 
the L-asparaginase enzyme in the serum, which leads to the asparagine amino acid 
depletion and tumor regression. In 1970s, the L-asparaginase became one of the 
important chemotherapeutic agents in ALL treatment protocols and the scientists 
started to use it in the treatment protocols of ALL patients to achieve remission 
(Rytting, 2012). 
The use of L-asparaginase depends on the fact that the leukemic lymphoblasts 
lack asparagine synthetase enzyme, which is essential for the synthesis of asparagine. 
Therefore, it depends entirely on external asparagine supplies to grow. L-Asparaginase 
enzyme results in the hydrolysis of asparagine amino acid producing ammonia and 
aspartic acid. In effect, asparaginase enzyme results in the selective death of cancer 
cells only due to depletion of asparagine amino acid. However, normal cells can 
synthesize their own asparagine using asparagine synthetase enzyme. The asparagine 
depletion causes an arrest in the cell cycle at the G1 phase as well as an impairment in 
the cancer cell’s DNA, RNA and protein synthesis  resulting in cancer cell death (Mu 
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& Boos, 1998). Therefore, L-asparaginase enzyme results in the selective death of 
cancer cells (Figure 3). 
Asparaginase is given in induction and maintenance phases of total XV 
protocol. In induction phase, the dose is 10,000 U/m
2
 taken intramuscular at days 6, 8, 
10, 12, 14 and 16 of the induction phase. Three extra doses can be given on days 19, 
21 and 23 if the patient residual leukemia cells at day 19 in the bone marrow are 
greater than or equal 1%. While in the continuation phase, dose and regimen differs 
according to the patient risk group. Low risk patients receive asparaginase on weeks 7-
9 and 17-19, three doses of 10,000 U/m2/dose weekly. On the other hand, standard and 
high risk patients receive 19 doses from week 1 till week 19, 1 dose weekly. Each dose 
is 25,000 units /m
2
 taken intramuscular (Pui et al., 2009). 
 
Image adopted from Critical Reviews in Oncology: Hematology 28 (1998) 97–113 
Figure 3: L- asparaginase Mechanism of Action. L-asparaginase hydrolyzes 
asparagine amino acid into ammonia and aspartic acid. In normal healthy cells, asparagine 
can be synthesized from aspartic acid and glutamine using asparagine synthetase enzyme. 
This enzyme is absent in Lymphoblastic leukemia cells so it depends on external asparagine 
amino acid. Using L- asparaginase results in depletion of asparagine amino acid and 
inhibition of protein synthesis in cancer cells. 
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1.2.2 Types of L-Asparaginase 
There are three types of L-Asparaginase commercially available in the market 
to date: asparaginase isolated from E.coli bacteria, Erwinia asparaginase extracted 
from Erwiniac hrysanthemi bacteria and the PEG asparaginase which is the peglated 
form of the E.coli asparaginase (containing polyethylene glycol) (Mu & Boos, 1998). 
L- Asparaginase hypersensitivity manifests in the form of anaphylactic or allergic 
reactions and can lead to the change to another asparaginase formulation in order to 
achieve the best outcome and the least side effects. 
The E.coli asparaginase is the native form of asparaginase as it is the oldest 
one in the market. Its half-life is 1.2 days, which is a moderate half-life in 
comparison with PEG and Erwinia asparaginase. If the patient has an allergic 
reaction from E.coli asparaginase, he should be shifted to the Erwinia asparaginase.  
The PEG asparaginase has a longer half-life than the native asparaginase. 
This means a lower number of doses will be given to the patient and therefore better 
patient compliance. Patients who have an allergic reaction from the peglated 
asparaginase should be shifted to the Erwinia asparaginase (Asselin et al., 1993).  
Erwinia asparaginase is used in patients have an allergy from both the 
pegelated or the native asparaginase its half-life is 0.65 day which is shorter than the 
peglated and the E.coli asparaginase. This short half-life result in increase the 
number of asparaginase doses taken by the patient to get the asparagine depleted 
(National Cancer Institute US, 2014; Rytting, 2012). 
It has been shown that the use of Asparaginase in ALL protocols increase the 
event free survival by 10% - 15% (Tong et al., 2014). Although the L-asparaginase is 
considered an important antitumor drug in the treatment protocol of ALL patients as 
it kills cancer cells without harming the normal body cells, L-asparaginase cause a 
wide spectrum of adverse reactions to the patients. The L- asparaginase side effects 
include severe allergic reactions, pancreatitis, hepatic dysfunction, hyperglycemia, 
hemostatic system alterations which appear in the form of thrombosis, bleeding and 
disseminated intravascular coagulation (DIC) (Pieters et al., 2012). In most of the 
protocols, L – asparaginase is left out from the consolidation phase and administrated 
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only in the induction and maintenance phases. Asparaginase can be administered 
either as an intramuscular injection or  intravenous infusion (Rytting, 2012). 
1.2.3 L-Asparaginase Side effects 
Hypersensitivity 
Hypersensitivity to asparaginase is one of the serious side effects that can 
take place after asparaginase administration. The risk of hypersensitivity incidence 
depends on prior administration of asparaginase and concomitant drugs in the 
treatment regimen (for example, steroids). The incidence of hypersensitivity reaction 
in ALL treatment protocols that include high dose corticosteroids in the induction 
phase is not frequent (Rytting, 2012). On the other hand, hypersensitivity is more 
frequent upon repeated administration of asparaginase without receiving steroids and 
its occurrence ranges from 5%–10% (Rytting, 2012; Storring et al., 2009; Vrooman 
et al., 2010). Although PEG-asparaginase cause less hypersensitivity than E.coli 
asparaginase, it still can cause allergic reactions associated with repeated doses of 
administration (Douer et al., 2007). Erwinia asparaginase can be used for patients 
having hypersensitivity from E.coli and PEG- asparaginase, where there is no cross 
reaction between E.coli and PEG- asparaginase antibodies and Erwinia asparaginase 
(Rytting, 2012). 
Pancreatitis 
The three types of L-asparaginase preparations can result in pancreatitis. A 
randomized clinical trial done on pediatric ALL patients using E.coli L- asparaginase 
versus PEG L- asparaginase for standard risk patients showed no difference in 
pancreatitis incidence rate between the two groups (Avramis et al., 2002). It was 
shown that pancreatitis incidence associated with asparaginase in pediatric ALL 
patients increase with patient age. This can give a hint that the pancreatitis incidence 
in Adult will be higher than in pediatric patients (Kearney et al., 2009). Generally, 
the pancreatitis incidence associated with asparaginase administration ranges from 
5%–10% (Avramis et al., 2002; Fu & Sakamoto, 2007). 
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Thrombus Formation 
Hemostasis is the mechanism where the body can control the bleeding from 
injured blood vessels by clot formation. Then the body dissolves clots that no longer 
needed. Blood clot is initiated from injury of wall vessel. Platelets accumulate 
rapidly at the injury site followed by accumulation of coagulation factors forming a 
clot. The coagulation factors are produced from a cascade of reactions to finally 
produce fibrin. Fibrin will form a mesh between the platelets aggregation causing 
clot stabilization. Any disturbance in the hemostatic system can result in excessive 
thrombosis or bleeding (Horne, 2005). 
Thrombus formation is a severe side effect that can takes place due to 
asparaginase administration. It usually takes place in the early phases of treatment 
and is related to different factors, such as central lines placement and 
hypercoagulability due to leukemia activity. The incidence of thrombus formation 
varies from 10% to greater than 30%. The incidence of thrombus increases with 
older age. It was reported that the incidence of thrombosis is the same when E.coli 
and Erwinia asparaginase are compared (Grace et al., 2011). The type of steroids 
used in the induction therapy also can affect the incidence of thrombus where it was 
reported that prednisolone is associated with higher incidence of thrombus
 
(Durden 
et al., 1983; Hernández-Espinosa et al., 2009; Nowak-Göttl et al., 2003). 
Once thrombus diagnosis is confirmed, low molecular weight heparin is used 
in the treatment of thrombus. Some studies showed the use of anti-thrombin III 
infusion as a supportive coagulation therapy, but its role in decreasing the thrombus 
incidence is not clear till now. A study was done on adult ALL patients showed a 
decrease in thrombotic events when anti-thrombin III was used as prophylactic 
infusion (Hunault-Berger et al., 2008). In order to avoid the L-asparaginase side 
effects and improve the treatment outcome for ALL patients different trials were 
tried, including using L-asparaginase from different sources and treatment schedules 
modifications to optimize the L-asparaginase use in the therapy. 
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1.3 Thrombosis in ALL 
Although ALL disease has a very good outcome reaches to 90% 5 years 
overall survival, the morbidity and mortality that result from toxicities of ALL 
therapy are significant. These toxicities can lead to therapy modifications that will 
affect the cure rate. Thrombosis is a well-known side effect associated with ALL 
treatment protocol leading to significant morbidity rates. The fatality rate is about 15 
% in those patients affected from thrombosis. The development of thrombosis can 
interfere with the treatment plan of ALL patients thus affecting the ultimate outcome. 
There are several studies that correlate the concomitant use of glucocorticoids and 
asparaginase with increasing incidence of the thrombosis (Pui et al., 2013). 
1.3.1 Incidence of Thrombosis in Children with ALL 
Thrombosis in children in general is an infrequent incidence. In general 
healthy pediatric population the incidence of pulmonary embolism (PE) and deep 
venous thrombosis (DVT) is 0. 7–14 events / 100,000 children (Monagle et al., 2001; 
Van Ommen et al., 2001). In comparison to the general estimates of thrombosis, the 
ALL pediatric patients are considered to be at much higher risk for thrombosis. The 
incidence of thrombosis in pediatric ALL patients ranges from 1.1% to 36.7% with 
an average of 3.2%. This wide range of variation in the reported thrombosis 
incidence is due to difference in the reported thrombosis definitions (asymptomatic 
vs. symptomatic), different treatment protocols used and diagnostic tools used for 
diagnosis and detection of the thrombosis (Athale & Chan, 2003a). 
The designed studies for evaluating asymptomatic thrombosis reported much 
higher thrombosis incidence when compared with other studies reporting 
symptomatic thrombosis only. For example, a PARKAA study whose objective was 
to compare ultrasonography to venography in the diagnosis of asymptomatic DVT in 
pediatric ALL patients reported a 36.7 % incidence of thrombosis (Male et al., 2002; 
Mitchell et al., 2003). On the other hand, other studies reported symptomatic 
thrombosis incidence ranges from 2.8% to 14.3%. This shows the importance of 
highlighting the thrombosis definition in the reported studies (Athale & Chan, 
2003a).  
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In addition to the previous discussed factors, the chemotherapy schedule has 
an important role in affecting the incidence of thrombosis incidence in pediatrics. 
When 2 different chemotherapy protocols were compared, Berlin-Frankfurt-Munich 
(BFM) and COALL protocols, it was found that although they treat the same ethnic 
population and in the same time frame, the thrombosis incidence in patients receiving 
BFM 90/95 protocol was 10 times higher than those receiving COALL 92/97 
protocol. This difference in thrombosis incidence was due to difference of the 
chemotherapy schedule in the 2 protocols (Mauz-Körholz et al.,2000; Nowak-Göttl 
et al., 1999, 2001). 
1.3.2 Locations of the Thrombotic Events in Children with ALL 
The majority of thrombosis events in children are of venous origin; however 
there are reports for thrombosis events of arterial origin. A large prospective meta-
analysis of 17 studies examined the venous thromboembolism (VTE) in ALL 
pediatric patients. The meta-analysis showed that symptomatic VTE was diagnosed 
in about 50% of the patients in the central nervous system (CNS), where infarction or 
stroke represents 18% and cerebral venous sinus thrombosis 28.6%. On the other 
hand, the study reported other locations for VTE including right atrium (1%), 
pulmonary embolism (1%), superficial VTE (2.2%) and the lower limbs (7.7%) 
(Caruso et al., 2006).  
Central venous lines (CVL) are great tools that have been used for more than 
20 years for children. It is used to maintain a venous access that facilitates the 
administration of blood products, chemotherapy and other supportive care 
medications. Central venous lines greatly improve the quality of life in pediatric 
cancer patients. Although there are several advantages for the use of CVL, its use is 
associated with both thrombosis and infections. Most thrombosis associated with 
CVL is asymptomatic and located at the catheter entry site into the vein. The CVL 
associated thrombosis occurs primarily in the upper venous system. It was reported 
in a meta-analysis that the incidence of upper limb thrombus and CVL was 27.5% 
(Caruso et al., 2006; Kenet et al., 2009; Mitchell et al., 2003). 
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1.3.3 Effect of Age and Gender on the Development of 
thrombosis 
The incidence of VTE in ALL patients is high in patients greater than 1 year 
and the incidence trend increase towards older children. On contrast, the VTE 
incidence in the normal pediatric population is higher in the neonatal period and less 
than 1 year of age (Athale et al., 2008; Caruso et al., 2006).  
The gender effect on the development of thrombosis is unclear. While some of 
the studies reporting gender distribution show female predominance or male 
predominance other studies show equal distribution(Athale & Chan, 2003a). (Pui 
et.al, 1985) reported male predominance in development of VTE. In contrast 
(Gugliotta et al., 1992), (Priest et al., 1982) and (Nowak-Göttl et al., 1999) reported 
female predominance. 
1.3.4 The Main Risk Factors that Affect Thrombus Formation 
in ALL Patients 
The Thromboembolism occurrence in ALL patients seem to be due to the 
interaction between the ALL disease, the therapy and the possible inherited genetic 
defects affecting the hemostatic balance (Athale & Chan, 2003b) (Figure 4). 
Risk Factor 1: Effect of Disease on Thrombosis 
At diagnosis, there is evidence of increased thrombin generation in children 
with ALL, the etiology of which is unclear. However, thrombosis in children with 
ALL is most commonly reported after the initiation of anti-leukemic therapy 
indicating a possible interaction of the disease and therapy (Athale & Chan, 2003b). 
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Figure 4: shows the 3 main factors involved in thrombosis pathogenesis in ALL 
patients. Development of thrombosis in ALL patients depends on the interaction between 
three main factors. The disease itself can produce a procoagulant state cause the patient at 
high risk of thrombus. The therapy can cause alteration in coagulation factors, in addition the 
patient himself may have an inherited prothrombotic disorders that can affect the thrombosis 
incidence susceptibility. In addition, other factors like having inflammation or central venous 
line may affect the thrombosis incidence. 
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Risk Factor 2: Effect of ALL Therapy on Thrombus 
Formation 
Asparaginase 
Asparaginase is a corner stone in most of contemporary All treatment 
protocols. However, L-asparaginase results in asparagine amino acid depletion, 
which can impair the coagulation cascade by reduction in coagulation factors and or 
inhibitors (Rizzari et al., 2014). 
Glucocorticoids 
It was found that glucocorticoids administrated concomitantly with 
asparaginase in ALL patients can affect the inflammatory reactions by inhibitory 
effects. The inhibitory effects can be divided into early and late effects. The 
glucocorticoids early effects are inhibition of capillary dilatation, inhibition of 
developing edema, as well as deposition of fibrin while late effects are proliferation 
of fibroblasts, capillary proliferation and collagen deposition. On the other hand, it 
was found that dexamethasone is more efficient in protection against thrombotic 
event versus prednisolone and that was explained by a stronger anti-inflammatory 
glucocorticoid effect (Goodman A & JG, 2001). 
A prospective multicenter study was done on pediatric ALL patients treated 
according to BFM protocol to assess the risk of symptomatic thrombus incidence in 
patients receiving either prednisolone or dexamethasone. The thrombus frequency in 
the prednisolone group was 10.4% while in the dexamethasone group was 1.8%. This 
study concluded that the use of dexamethasone instead of prednisolone in the  
induction phase can significantly reduce the thrombus onset in ALL pediatric 
patients (Nowak-Göttl et al., 2003). 
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Risk Factor 3: Effect of Inherited Thrombophilia on the 
Development of Thrombosis 
Blood coagulation is an important mechanism that protects our body from 
bleeding. The key enzyme of the coagulation system is the thrombin enzyme. It 
converts fibrinogen to fibrin to form the fibrin mesh which occludes the vascular 
injury and has a feedback effect for the amplification of the coagulation process. The 
adequate amount of thrombin at injury sites results from a cascade of reactions called 
coagulation cascade. It is triggered by endothelium injury which led to blood 
exposure to the extravascular tissue. In normal conditions, there is a harmony 
between the procoagulant system, which induce coagulation and the anticoagulant 
system which controls its effect. Any disturbance in this natural balance due to 
genetic or acquired reasons may lead to thrombotic or bleeding diseases (Dahlbäck, 
2000). Most of the factors that alter an individual’s thrombosis risk are related to an 
alteration in the normal balance that exists between the procoagulant and the 
anticoagulant state. 
Regulation of the blood coagulation process is important in order to prevent 
its generalized or continuous activation, which can lead to thrombus formation. The 
coagulation system must be active only in case of injury and for sufficient time to 
control bleeding by the formation of a fibrin clot.  In order to achieve this balance, 
there are a number of regulatory mechanisms that are activated in order to control the 
effect of activated coagulation factors such as FIXa, FXa, FVa and FVIIIa. There are 
anticoagulant cofactors and proteins responsible for binding to the activated 
coagulation factors to limit their activity, for example, protein C, protein S and anti-
thrombin. Anti-thrombin inactivates many activated coagulation factors such as 
thrombin, FIXa, FXa and TF-VIIa complex. Protein S acts as a cofactor for activated 
protein C (APC) forming a protein S/APC complex. This complex is able to 
inactivate FVa and FVIIIa, which are responsible for the conversion of the inactive 
prothrombin to thrombin, and thus in effect the S/APC complex controls thrombin 
production  (Dahlbäck, 2000; Norris, 2003). 
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Thrombophilia refers to a group of conditions that make an individual more 
susceptible for having clots than normal. Inherited thrombophilia (IT) can affect 
ALL patients’ thrombus incidence risk and may be used as a predictive tool for 
thrombus prevention. Although it is an important risk in thrombus formation; 
however it is still not clear till now how the thrombophilia screening will help in 
decreasing the thrombus incidence rate (Revel‐Vilk et al., 2003). 
A classification system for inherited prothrombotic defects divided these 
conditions into two groups. Group 1 disorders: hereditary deficiencies of anti-
coagulation factors (Anti thrombin III deficiency, protein C deficiency and protein S 
deficiency). Group 2 disorders: hereditary disorders associated with the increase in 
the levels or function of coagulation factors (Factor V Leiden, PT gene mutation, 
elevated level of homocysteine, elevated levels of lipoprotein (a), elevated levels of 
factors VIII, IX and XI) (Athale & Chan, 2003b).  
It was reported in literature that inherited thrombophilia has an important role 
in increasing thrombus risk in ALL patients. A prospective multicenter study was 
done on patients treated on treatment protocol BFM 90/95 to assess the risk of 
thrombus in pediatric ALL patients. The study showed that the thrombus risk was 
much higher in patients with inherited thrombophilia defect (46.5% vs. 2.2%, P < 
0.001). In addition, thrombus risk was higher in patients with multiple inherited 
thrombophilia defects when compared to those with single inherited thrombophilia 
defect (P =0.009) (Nowak-Göttl et al., 1999). In contrast, PARKAA study reported 
no correlation between inherited thrombophilia defects and thrombus formation 
(Mitchell et al., 2003). 
A meta-analysis concluded that inherited thrombophilia can increase the risk 
of thrombosis by 8 folds (Caruso et al., 2006). There is a current debate in the field 
regarding the role of inherited thrombophilia (IT) on the incidence of thrombosis in 
ALL patients and its importance as a predictive tool for asparaginase-related 
thrombus formation. This debate and difference in results is due to different 
treatment protocols used and the different populations with ethnic variability. That is 
why it is important to screen ALL pediatric patients in the Egyptian population for 
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inherited thrombophilia in order to examine its role on asparaginase-related thrombus 
formation. 
 
IT Factor 1: Factor Five Leiden 
Factor V is a coagulation factor whose active form is known as FVa. FVa has 
an important role in the production of thrombin from the inactive prothrombin.  
Therefore, an increase in the levels of FVa will lead to an increase in thrombin 
production resulting in a hyper coagulopathy state. Normally, Activated protein C 
(APC) has an inhibitory effect on factor V and thus an inhibitory effect on the 
conversion of prothrombin to thrombin. However, it was found that in some patients, 
factor V will show resistance against APC and will not be inactivated. This was later 
found out due to a point mutation in the FV gene, referred to as FV Leiden mutation 
(Norris, 2003). This mutation results in the replacement of arginine with glutamine at 
codon 506 and thus a loss of one of the three APC cleavage sites in factor Va which 
leads to an impaired ability of APC to degrade factor Va resulting in the Activated 
protein C resistance phenomena (Dahlbäck, 2000).  
In 1993, it was reported as unusual phenomena while studying the effect of 
adding external activated protein C (APC) to venous thromboembolism (VTE) 
patient’s plasma. They were expecting slowing down in the coagulation process upon 
adding the APC, as FV will be inactivated. However, they noticed that in some 
patients the slowdown of the coagulation process did not occur and they called this 
phenomena as APC resistance (Carlsson & Svenssont, 1993). After one year, another 
team of researchers discovered a point mutation in FV gene where Guanine is 
replaced by Adenine at position 1691of exon 10 of the gene. This mutation was 
called FV Leiden according to the city they were doing their research in. This point 
mutation causes a change in the amino acid coding for arginine at codon 506 
changing it to glutamine (Bertina et al., 1994). Because of this change in the FV gene 
the APC enzyme cannot recognize the FV effectively and the FV remains active 
causing hyper coagulopathy state. This lead to interruption for one of the most 
important regulatory pathways in the coagulation cascade which may be a risk factor 
for VTE (Jadaon, 2011a). 
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Since the discovery of the FV Leiden, many studies were done to know the 
prevalence of FV Leiden in patients with VTE and healthy populations. It was found 
that Factor V Leiden has high prevalence in Europe especially in the Caucasian 
population. Factor V Leiden prevalence in healthy Caucasian population is (1-15%) 
while in patients with VTE is (15-65%). On the other hand, FV Leiden prevalence in 
other ethnic groups like Africans, Japanese, Chinese, and South-East Asians is 
almost rare. It was suggested that the FV Leiden mutation first occurred in an old 
ancestor of the European Caucasian population (Jadaon, 2011a). The highest 
prevalence of the FV Leiden mutation is found in Europe; especially in Germany, 
Sweden and Cyprus. It is also common in Saudi Arabia (Rees, 1996). 
IT Factor 2: Prothrombin Gene Mutation 
Prothrombin has an important role in the coagulation cascade. Blood 
coagulation is initiated by a blood vessel injury then a biochemical cascade starts to 
block the injured vessel by a blood clot. The coagulation cascade consists of a large 
number of proteins and enzymes called coagulation factors. Thrombin is an 
important coagulation factor produced in the liver in an inactive form, known as 
prothrombin. Prothrombin circulates in the blood stream till it is activated, as in the 
case of a blood vessel injury for example. Prothrombin at this point is activated  to 
thrombin by a coagulation factor called factor X. Thrombin  is essential for the 
formation of a fibrin clot by converting fibrinogen (factor I) to fibrin, thus leading to 
the blockage of the injured blood vessel by a mesh like structure (Jadaon, 2011b). 
In 1996, it was reported by Poort et al. that the prothrombin gene G20210A 
mutation is a cause for venous thrombosis. Prothrombin G20210A mutation results 
in increased levels of prothrombin in plasma causing a higher risk of thrombus  
formation (Poort et al., 1996). Prothrombin G20210A gene mutation is a point 
mutation. This point mutation involves a replacement of an adenine with guanine at 
20210 position on prothrombin 3' untranslated region (3' UTR) (Pollak, Lam, & 
Russell, 2002). A study investigated the effect of the G20210A mutation on the 
mRNA and protein expression of prothrombin. The study reported that this mutation 
affects the polyadenylation site of the prothrombin gene, increasing prothrombin 
mRNA and protein synthesis, with a subsequent increase in prothrombin plasma 
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levels(Ceelie et al., 2004). An increase in prothrombin production thus leads to a 
higher tendency for clot formation. This condition is called hyper coagulopathy, 
whereby a patient will be at a higher risk of thrombus formation than normal, by 2 
folds (Poort et al., 1996). 
Prothrombin G20210A mutation has a prevalence of 2% in white Caucasian 
population (Atasay et al., 2003). It is more prevalent in Southern European than in 
Northern European. It is rare in people from Asian and African descent (Rosendaal et 
al., 1998). Individuals with a G20210A mutation suffer from an increased risk of 
thrombosis by 2-3 folds (Bounameaux & Rosendaal, 2011). 
IT Factor 3: Elevated Level of Homocysteine 
Homocysteine (Hcy) is an intermediate product produced from methionine 
conversion to Cysteine. Homocysteine in normal circumstances is catabolized into 
cysteine by transulfuration pathway or can be processed back to produce methionine 
amino acid by remethylation pathway (Figure 5). Hyper homocysteinaemia results 
from MTHFR polymorphism. Methylene tetra hydrofolate Reductase (MTHFR) is an 
important enzyme in folate metabolism. In addition, it is a cofactor in homocysteine 
re-methylation process to produce methionine. Therefore, reduction in MTHFR 
enzyme cause increase in homocysteine plasma level. There are 2 common genetic 
polymorphisms associated with low function of MTHFR gene: MTHFR A1298C and 
MTHFR C677T (Athale & Chan, 2003b). The MTHFR C677T polymorphism takes 
place in exon 4 resulting in substitution of Alanine to Valine at codon 222 (Tantawy 
et al., 2010). 
Hyper homocysteinaemia can also result from other factors like methotrexate 
chemotherapy (antifolate medication), vitamin B12, folate, vitamin B6 deficiencies 
(Girling, 2001). It was found that an elevated homocysteine plasma level is an 
independent risk for venous thrombosis and arteriosclerotic vascular disease. The 
exact mechanism of thrombosis associated with high homocysteine plasma level is 
unknown (Athale & Chan, 2003b; Crowther & Kelton, 2003). 
MTHFR C677T polymorphism is associated with high levels of fasting Hcy 
plasma levels. This mutation is a risk factor for thrombosis development especially in 
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case of folate deficiency (Frosst et al., 1995). There is a high variation in MTHFR 
polymorphism among different population. In Asia and Europe, there is a north to 
south increase gradient, while in the sub Saharan African population the mutation 
prevalence is very low. On the other hand, there is a high prevalence of this mutation 
in the Mediterranean region (Bauduer & Lacombe, 2005). The prevalence differs in 
different ethnic groups and ranges from 2% to 54.5% (G.Pepe et al. 1998). 
1.3.5 Inherited Thrombophilia in Cancer Patients 
There are several studies done on FV Leiden, MTHFR C677T and 
Prothrombin G20210A mutations to investigate their role as a risk factor for 
thrombus in cancer patients but the results appear controversial (Akın et al., 2012; 
Haim et al., 2001; Mitchell et al., 2003; Otterson et al., 1996; Ramacciotti et al., 
2003; Ravin et al., 2002). This difference in results between different studies may be 
due to a difference in population under study and/or there may be other factors in the 
coagulation cascade having a role in synergistic the hyper coagulopathy effect of the 
studied mutations. 
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Figure 5: Shows the normal mode of action of MTHFR enzyme. In normal 
metabolism, homocysteine (Hcy) is converted to methionine via a trans- methylation reaction 
in the presence of methionine synthetase, which catalyses the transfer of a methyl group from 
5-methyltetrahydrofolate to homocysteine forming methionine and tetrahydrofolate. On the 
other hand, Hcy is converted in a certain proportion to Cysteine through transsulfuration 
pathway. MTHFR convert 5, 10- methylene-tetrahydrofolate   to 5 methyl tetrahydrofolate 
(5MTHF) ensuring continuous supply of 5MTHF and thus allowing the production of 
methionine. MTHFR polymorphism affects the Hcy re methylation process and result in 
increase in homocysteine plasma level. In addition,  5,10- methylene-tetrahydrofolate act as 
methyl group donor which allow the conversion of (dUMP) to deoxthymidine monophosphate 
(dTMP) in the presence of thymidylate synthase enzyme result in DNA synthesis. 
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1.4 Aim of the Work 
As more insight should be gained in the field of thrombophilia, it becomes 
important to re-examine this old problem in the context of the pediatric Egyptian 
ALL patients. This will enable us to identify patients at risk for thrombosis, and may 
help to develop therapeutic and/or preventive strategies.  
The main objectives of this study were: 
1. To assess the prevalence of prothrombotic defects (FV Leiden, MTHFR C677T 
and prothrombin G20210A mutations) in Egyptian pediatric ALL patients.  
2. To estimate the impact of inherited Thrombophilia (IT) on the risk of thrombosis 
onset in pediatric ALL patients that can guide therapy modification and thrombo-
prophylaxis, if indicated.  
3. To evaluate the impact of the presence of single versus multiple IT prothrombotic 
mutations on thrombosis. 
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2. Subjects and Methods 
2.1 Subjects 
Sixty three pediatric ALL patients with thrombotic event ( age more than 1 
year & less than 18 years old at diagnosis) treated with ALL protocol adopted from 
SJCRH study XV for low or standard/high risk at the Children’s Cancer Hospital in 
Egypt (CCHE) during period between August 2009 and September 2013. While the 
control group included 63 ALL patients without thrombotic event treated at CCHE 
with same protocol and matched for age, gender, IPT and risk stratification. 
Subjects were excluded if they were: 
- Non-Egyptian ALL patients.  
- Their ages were less than one year or greater than 18 years at diagnosis. 
- Patients with Down syndrome or having other syndromes to avoid any other 
factors that may affect their risk of thrombosis. 
 
The ethical committee of CCHE and the American university in Cairo approved 
the study and a written informed consent was obtained for each patient’s guardian 
according to the guidelines of the Helsinki declaration.  
After the patient had got thrombosis, he is treated with Low molecular weight 
heparin with a therapeutic dose till the thrombus become stationary or recanalized 
followed by prophylactic dose. Radiological diagnosis and assessment is done by 
using Doppler flow in cases of DVT & MRI +/- MRV in case of brain thrombosis to 
check thrombosis status. Clinical data collected included: patient’s age at diagnosis, 
gender, risk stratification, Immunophenotyping, initial TLC and patients’ outcome. 
Number of L-asparaginase doses before event, treatment modifications, site of 
thrombus, symptoms and complications associated with thrombus and either the 
patient was rechallenged with L-asparaginase after the event or not was also collected. 
Acute Lymphoblastic Leukemia patients were treated according to Saint Jude 
Total XV protocol without the up-front window phase ( Pui et al., 2009). They were 
subjected to initial work-up to confirm ALL diagnosis which included: CBC at 
diagnosis, bone marrow examination, immunophenotyping (IPT), DNA index, 
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molecular translocations, cytogenetic karyotyping (Coustan-smith et al., 2000). The 
treatment protocol started with remission-induction phase (42 days) in which patients 
received prednisone, L-asparaginase (E.Coli), cytrabine, doxorubicin, vincristine, 6-
mercaptopurine and cyclophosphamide. According to patient initial characteristics 
and response at remission date (Day 42), each patient was assigned to low risk (LR), 
standard risk (SR), or high risk (HR) at the end of induction. Consolidation phase (8 
weeks) followed the induction period, consisted of four cycles of HD-MTX given 
every other week. Then L asparaginase continued again in continuation phase, where 
for SR/HR patients they receive weekly L Asparaginase till Week 19, While LR 
patients received L asparaginase every other day (3 doses /week) on weeks7-9 and 
weeks 17-19. Continuation phase lasted for 146 weeks for boys and 120 weeks for 
girls (Pui et al., 2009). 
2.2 Blood sampling 
   All the forthcoming procedures were performed at the molecular biology unit 
at the laboratory department, CCHE-57357. Blood samples (2-5ml each) were 
withdrawn from patients. Tubes containing disodium ethylene diamine tetra-acetic acid 
(EDTA) were used (Diagnostics, Franklin Lakes, NJ, USA). 
2.3 DNA Extraction 
DNA was isolated from peripheral blood to study the selected genes. DNA was 
extracted using Gene JET Genomic DNA Purification Kit (Thermo scientific, #K0721) 
in accordance to the manufacturer instructions. The isolated DNA concentration was 
measured using NanoDrop spectrophotometer (NanoDrop 2000, USA). The O.D (optical 
density) was measured at wavelength A260nm and A280nm. 
2.4  MTHFR C677T gene genotyping 
   Detection of MTHFR C677T mutation was performed by PCR-RFLP 
technique (restriction fragment length polymorphism). Primers, restriction enzyme and 
fragments obtained are presented in table 1 (Tantawy et al., 2010). 
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Table 1: Primers, restriction enzyme and fragments produced from MTHFR 
C677T gene digestion. 
 
Gene 
 
Primer sequence 
Restriction enzyme Restriction 
condition 
Fragment 
Parameter 
MTHFR 
C677T 
 
Forward primer 
5’TGAAGGAGAAG
GTGTCTGCGGGA3’ 
 
Reverse primer: 
5’AGGACGGTGCG
GTGAGAGTG 3’ 
HinfI fast digest 
(10U/1µl) 
(Thermo scientific, 
FD0804) 
1µl at 37°C 
for10 
minutes. 
Wild type: 198 
base pair. 
Heterozygous: 
198, 175, and 
23 base pair. 
Homozygous: 
175 and 23 
base pair. 
 
 The amplification was done using [8 x 11 cm (Bio-Rad mini sub cell® GT 
712Br)]. The total volume for the PCR reaction was 25 µl, and the components of 
each reaction were: 1 µl extracted DNA (50 ng/1µl), 0.25µl (1 unit) DFS-Taq DNA 
Polymerase, (BIORON, Germany), 2.5 µl10X Buffer, 2.5 µl (10 mM) Deoxynucleotide 
triphosphates (dNTPs) (Thermo Scientific, #R0181), 1.25µl (10 µM) MTHFR F primer, 
1.25µl (10 µM) MTHFR R primer (Table 1), then 16.25 µl PCR Water was added to 
complete the reaction volume to 25µl. 
   The PCR conditions for MTHFR gene amplification were: initial denaturation 
at 95
o
C for 2 minutes, followed by 40 cycles of: denaturation (94
o
C for 15 sec), 
annealing (72
o
C for 15 sec) and extension (72
o
C for 30 sec). Then final extension step 
at 72
o
C for 1 minutes. An aliquot (5 µl ) from the  PCR product was run on 2% 
agarose gel (Lonza) at 100 volt for 20 minutes against a DNA ladder Gene Ruler 100 bp 
(Thermo Scientific, #SM0241) to check the presence of the amplified product.  
The MTHFR amplicon was 198 bp fragment. The amplicon was digested using 
sequence depending endonuclease fast digest enzyme [HinfI] (1 µl/10 U, 37°C for 10 
minutes). Digested fragments were visualized on UV trans illuminator after vertical 
electrophoretic separation (Bio-Rad Mini-PROTEAN® 3 cell 525 BR) at100 V for 120 
min. on a 15% acrylamide gel. Digestion of the amplicon for MTHFR C677T gene 
polymorphism yielded bands of 198 bp in CC wild type, 175 bp, 23bp in TT 
homozygotes, and all 3 bands (198, 175, and 23 bp) in CT heterozygotes (Figure 6). 
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Undigested 
 
                                     198 bp 
Wild 
 
                                     198 bp 
Homozygous 
                                 
                                     175bp                  23bp 
Heterozygous 
 
                                      198 bp 
 
                                     175bp                   23 bp 
 
Figure 6: The digestion of DNA by HinfI enzyme in case of normal and mutant 
MTHFR C677T alleles. The MTHFR C677T polymorphism creates a restriction site for 
HinfI digest enzyme. The digestion of the PCR product showed production of 198 bp in CC 
wild type. Heterozygous allele produced 3 bands: 198, 175 and 23 bp. Homozygous allele 
produced 2 bands: 175 bp, 23bp. 
2.5 Factor V Leiden gene genotyping 
   Detection of Factor V Leiden was performed by PCR-RFLP technique 
(Abdullah et al., 2010). Primers, restriction enzyme and fragments obtained are 
presented in Table 2. 
Table 2: Primers, restriction enzyme and fragments produced from FV Leiden 
gene digestion. 
Gene 
Mutation 
Primer sequence Restriction 
enzyme 
Restriction 
condition 
Produced 
Fragments size 
FV 
Leiden 
G1691A 
 
Forward primer:      5' 
GGA ACA ACA 
CCA TGA TCA 
GAG CA -3' 
 
Reverse primer: 
5' TAG CCA GGA 
GAC CTA ACA 
TGT TC -3' 
 
MnII fast 
digest 
(10U/1µl) 
(Thermo 
scientific, 
FD1074) 
1µl at 
37°C 
for10 
minutes. 
Wild type:  
157, 93 and 37 bp 
Heterozygous: 
157, 130, 93 and 
37 bp. 
Homozygous:  
157 and 130 bp 
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   The amplification was done using [8 x 11 cm (Bio-Rad mini sub cell® GT 
712Br)]. The total volume for the  PCR reaction was 25 µl, and the components of 
each reaction where: 2.5 µl 10X Buffer, 2.5 µl (10 mM) Deoxynucleotide triphosphates 
(dNTPs) (Thermo Scientific, #R0181), 1.25µl (10 µM) FV F primer, 1.25µl (10 µM) FV 
R primer (Table 2), 1 µl extracted DNA (50ng/1 µl), 0.25µl (1 unit) DFS-Taq DNA 
Polymerase (BIORON,Germany)  then 16.25 µl PCR Water was added to complete the 
reaction volume to 25µl. 
   The PCR conditions for FV gene amplification were: initial denaturation at 
94 
o
C for 2 minutes, followed by 40 cycles of: denaturation (94
 o
C for 15 sec), 
annealing (55
o
C for 15 sec) and extension (72
 o
C for 30 sec). Then final extension 
step at 72
 o
C for 1 minutes. An aliquot (5 µl) from the PCR product was run on 2% 
agarose gel (Lonza) at 100 volt for 20 minutes against a DNA ladder Gene Ruler 100 bp 
(Thermo Scientific, #SM0241) to check the presence of the amplified product. 
   The presence of FV Leiden mutation removes the MnII digest enzyme 
restriction site. The FV amplicon size was 287 bp fragment. The amplicon was digested 
using sequence depending endonuclease fast digest enzyme [MnII] (1 µl/10 U, 37°C for 
10 minutes). Digestion of the amplicon for FV Leiden gene polymorphism yielded bands 
of 3 fragments: 157 bp, 93 bp, and 37 bp in GG wild type while157bp, 130 bp in AA 
homozygotes, and all 4 bands 157, 93, 130and 37bp in GA heterozygotes (Figure7). The 
digested fragments were visualized on UV Trans illuminator after vertical 
electrophoretic separation (Bio-Rad Mini-PROTEAN® 3 cell 525 BR) at100 V for 120 
min. on a 15% acrylamide gel. 
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Undigested 
 
                                     287 bp 
Wild 
 
                     157 bp                    93 bp       37 bp 
Homozygous 
                                 
                            157 bp                      130 bp 
Heterozygous 
 
                 157 bp                        93 bp         37 bp 
 
                    157bp                            130 bp 
 
Figure 7: The digestion of DNA by MnII in case of normal and mutant FV 
alleles. The presence of FV Leiden mutation removes the MnII digest enzyme restriction 
site. The PCR product digestion showed production of 157, 93 and 37 bp bands in case of 
wild type. In case of heterozygous alleles, 157, 130, 93 and 37 bp bands were produced, 
while homozygous allele showed 157 and 130 bp bands. 
 
2.6 Prothrombin G20210A genotyping 
   Detection of PT G20210A mutation was performed by Allele specific PCR 
Technique (ASPCR). For each patient 2 reactions were performed one reaction 
containing the mutation primer while the other reaction contains wild type primer. FIX 
primers were used in both reactions to detect factor IX gene as an internal control 
(Ranguelov et al., 2002). The primers used in amplification of the PT gene are shown in 
Table 3. 
The ASPCR is a modified technique of standard PCR that allows efficient SNPs 
discrimination. Where 2 forward (Mutation or wild type primer) and 1 reverse primers 
(common) are used in 2 different tubes. Where Tube M contains the entire reaction 
component without the wild type primer and it is supposed to detect if the patient has 
SNP. Normally, if the patient is normal only the internal control band will appear at 
219 bp in this lane. While tube N contains the entire reaction components except the 
Mutation primer, this reaction is supposed to detect if the patient has a wild type 
allele or not. If the patient is heterozygous or wild type a band will appear at 340 bp 
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plus the internal control band. While if the patient is homozygous only the internal 
control band will appear at 219 bp  (Figure 8) (Ranguelov et al., 2002). 
Table 3: Primers used in PT G20210A Allele Specific PCR  
Primer Sequence 
PT Reverse 
(Common) 
5’-TCT AGA AAC AGT TGC CTG GCA G-3’ 
PT Forward 
(WT) 
5’-GCA CTG GGA GCA TTG AGG ATC-3’ 
PT Forward 
(Mutant) 
5’-GCA CTG GGA GCA TTG AGG ATT-3’ 
FIX-Forward 5’-CTC CTG CAG CAT TGA GGG AGA TGG ACA TT-3’ 
FIX-Reverse 5’-CTC GAA TTC GGC AAG CAT ACT CAA TGT AT-3’ 
 
    The amplification was done using [8 x 11 cm (Bio-Rad mini sub cell® GT 
712Br)]. The total volume for the  PCR reaction was 25 µl, and the components of 
each reaction where: 1 µl extracted DNA (50ng/1 µl), 0.25µl  (1 unit) HOT FIRE POL 
hot start DNA Polymerase (SolisBioDyne,01-02-00500 ), 2.5 µl 10X Buffer B1 
(Without MgCl2 or detergent), 2.5 µl (10mM) Deoxynucleotide triphosphates (dNTPs) 
(Thermo Scientific , #R0181), 2.5 µl (25 mM) MgCl2, 1.25µl (10µM) PT Common 
primer Table 3, 1.25µl (10µM) PT wild primer (N reaction only), 1.25µl (10µM) PT 
Mutation primer (M reaction only), 1.25µl (10µM) FIX- Forward primer, 1.25µl (10µM) 
FIX- Reverse primer then 11.25 µl PCR Water was added to complete the reaction 
volume to 25µl. 
The PCR conditions for PT gene amplification were: initial denaturation at     
95 
o
C for 10 minutes, followed by 10 cycles of: denaturation (94
 o
C for 30 sec), 
annealing (60
o
C for 30 sec) and extension (72
 o
C for 60 sec). Then repeat the 
following steps for 25 cycles: 30 seconds at 94 °C, 30 seconds at 55 °C and 1 minute 
72°C. Then final extension step was run at 72
 o
C for 7 minutes. Twelve µl from each 
PCR product was run on 2% agarose gel (Lonza) at 100 volt for 30 minutes against a 
DNA ladder Gene Ruler 100 bp (Thermo Scientific, #SM0241) to check the presence of 
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the amplified product. 
 
Figure 8: Prothrombin Allele Specific PCR expected bands in both M and N 
lanes. M lane represents the PCR product when the mutant forward primer was used, while 
N lane represents the PCR product when the wild type allele forward primer was used. The 
wild type allele shows 340 and 219 bp bands in the N lane while 219 bp band only produced 
in the M lane. The heterozygous allele shows 340 and 219 bp bands in both lanes N and M. 
The homozygous allele shows 219 bp band in N lane while 340 and 219 bp bands produced 
in M lane. 
 
2.7 Statistical Methods 
   Data was analyzed using IBM SPSS advanced statistics version 20 (SPSS 
Inc., Chicago, IL). Numerical data were expressed as mean and standard deviation or 
median and range as appropriate. Qualitative data were expressed as frequency and 
percentage. Chi-square test or Fisher’s exact test was used to examine the relation 
between qualitative variables. For not normally distributed quantitative data, 
comparison between two groups was done using Mann-Whitney test (non- 
parametric t-test). Survival analysis was done using Kaplan-Meier method and 
comparison between two survival curves was done using log-rank test. Odds ratio 
(OR) with it 95% confidence interval (CI) were used for risk estimation. All tests 
were two-tailed. A p-value < 0.05 was considered significant. 
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3. Results 
One hundred twenty six ALL patients were enrolled in this study and divided 
into 2 groups. The 1
st
 group included patients with thrombus and the 2
nd
 group is the 
control group. Patients descriptive data were collected from the hospital medical 
records (archived files and electronic medical records) for both control and thrombus 
groups.  
Out of a total 889 Egyptian patients treated with ALL protocol (age more 
than 1 year and less than 18 years old at diagnosis) adopted from SJCRH study XV 
for low or standard/high risk at the Children’s Cancer Hospital in Egypt (CCHE) 
during period between August 2009 and September 2013, 84  patients had thrombus. 
There were 8/84 patients died with no sample, 6/84 patients refused to participate, 
1/84 lost follow up, 1/84 had Marfan syndrome and 5/84 were down syndrome. The 
final number of thrombus patients enrolled in the study was 63/84. 
3.1 Patients' characteristics 
In both groups the patients age, Gender, initial total leukocyte count (TLC), 
immunophenotyping (IPT) and risk at diagnosis were comparable (Table 4). The 
patients were divided according to age into 3 subgroups, from 1 to less than 5 years, 
from 5 to less than 10 years and from 10 to 18 years. 
 In thrombus group, the patients’ age trend was higher in the sub group from 
10-18 years (52.4%) in comparison to the other 2 sub-groups. Most of the thrombus 
patients were diagnosed as standard/high risk (80.9%) while the low risk patients 
were 19%. The Male patients represented 69.8% of the total thrombus group. The 
initial TLC was less than 100 x10
3
/ml in 85.2% and the immunophenotype was 
(68.3%) of B cell origin. 
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Table 4: Clinical characteristics of the enrolled patients with and without 
thrombus  
 Cases 
N (%) 
Control 
N (%) 
P Value 
Age at diagnosis 
(years) 
              1-<5 
5-<10 
10-18 
 
Mean = 9.4 
11 (17.5) 
19 (30.2) 
33  (52.4) 
 
Mean = 8.8 
11 (17.5) 
19 (30.2) 
33  (52.4) 
0.536 
Initial TLC (103/ml) 
< 100 
>=100 
Missing 
Mean = 38.5 
52 (85.2%) 
9 (14.8%) 
2 
Mean = 63 
51 (81%) 
12 (19%) 
NA 
0.524 
Gender  
Male 
Female 
 
44 (69.8%) 
19 (30.2%) 
 
43(68.3%) 
20 (31.7%) 
0.847 
Risk 
Low Risk 
Standard Risk 
High Risk 
 
12 (19%) 
44 (69.8%) 
7 (11.1%) 
 
15 (23.8%) 
40 (63.5%) 
8 (12.7%) 
0.744 
Immunophenotype 
B cell 
 
43 (68.3%) 
 
44 (69.8%) 
 
 
 
 
 
 
 
 
 
 
 
 
0.847 
B Precursor 
undifferentiated 
0 (0%) 
 
1 (1.6%) 
 
C-ALL                          26 (41.3%) 
 
28 (44.4%) 
 
Pre-B                         
 
14 (22.2%) 
 
14 (22.2%) 
 
Pro-B 
 
3 (4.8%) 
 
1 (1.6%) 
 
T cell 
 
20 (31.7%) 
 
19 (30.2%) 
 
T early 
 
11 (17.5%) 
 
7 (11.1%) 
 
T intermediate 
 
7 (11.1%) 
 
11 (17.5%) 
 
T late                          
 
0 (0%) 
 
1 (1.6%) 
 
T cell  
undifferentiated  
 
2 (3.2%) 
 
0 (0%) 
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3.2 Thrombus Timing 
In 42/63 patients (66.7%) the incident took place during the induction phase 
while 21/63 patients (33.3%) had the incident during the continuation phase. The 
incident here is thrombus ± infarction (Table 5). Thrombosis that occurred between 
the first dose of asparaginase and the last dose of asparaginase at week 19 was 
included in the analysis. 
3.3 Number of Doses Before the Thrombosis 
The L-asparaginase doses taken before the incident were classified into 3 
groups: 1- 4 doses, 5-9 doses and greater than or equal 10 doses. Seventeen patients 
(26.9%) had from 1 to 4 doses before the event, 26/63 patients (41.2%) had from 5 
to 9 doses before the event, 20/63 patients (31.7%) had greater than 10 doses before 
the event (Table 5). 
3.4 Treatment Modifications 
Out of the 63 patients with thrombosis 47 patients (74.6%) had treatment 
modifications and the rest continued the treatment protocol smoothly. The number of 
patients who skipped L-asparaginase doses was 43 (68.3%) while four patients had 
delayed treatment without omitting doses (Table 5).    
3.5 Rechallenge with L - Asparaginase After Thrombosis 
In the thrombosis group, 56/63 patients (88.9%) were rechallenged 
(restarted) with L- asparaginase after the event and 7/63 (11.1%) patients stopped L-
asparaginase for the rest of the protocol. Progression took place in 15 rechallenged 
patients (15/56 = 26.7%), while 41/56 patients (73.2%) continued the L –
asparaginase smoothly. Asparaginase was rechallenged after diagnosis of thrombosis 
with a median duration of 10 weeks (Table 5). 
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Table 5: Characteristics of pediatric ALL thrombus group  
 Cases 
N (%) 
Type of incidence  
Thrombus only 
Thrombosis with infarction 
               Hemorrhagic infarction 
               Non hemorrhagic infarction 
 
58 (92.1%) 
5   (7.9%) 
2/5 
3/5 
Treatment phase at time of the event: 
Induction 
Continuation 
 
42 (66.7%) 
21 (33.3%) 
Number of L-Aspara doses before event  
 
1-4 doses 
 
              5-9 doses 
 
≥10 doses 
Median =6 (Min=1& Max=28) 
 
17 (26.9 %) 
 
26 (41.2%) 
 
20 (31.9 %) 
 
Treatment Modifications  
No 
Yes  
Delayed Aspara doses  
Number of patients  
Duration (days) 
 
Omitted Aspara doses 
 Number of patients  
 Number of doses omitted: 
                 
                                     1-4    doses 
                                     5-9    doses 
                                    10-17 doses 
 
16 (25.4%) 
47 (74.6%) 
 
4/63 (6.3%) 
(Median =14,Min.= 4 & Max=49 ) 
 
 
43/63 (68.3%)  
(Median =3.5, Min=1 & Max=17 ) 
 
28/43 (65.1%) 
7/43   (16.2 %) 
8 /43  (18.6 % ) 
 
Rechallenge of L-asparaginase 
No 
Yes 
          Progression on rechallenge: 
 
No 
Yes 
 
7   (11.1%) 
56 (88.9%) 
 
 
41/56 (73.2%) 
15/56 (26.8%) 
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3.6 Outcome and prognosis 
Symptoms associated with the thrombus included headache 52%, convulsions 
21.3%, blurred vision (8%), vomiting (8%), lower limb Swelling and pain (9.3%.) 
and dysphagia due to laryngeal paralysis (1.3%) (Table 6). On the other hand, about 
10% of the thrombus patients were associated with comorbid complications such as 
hemiplegia, hypotonicity and tremors that lasted with the patient for 18 months 
(Table 5). Those patients with comorbid complications were associated with CNS 
thrombosis. The Event free survival (EFS) is the duration from the start of treatment 
till relapse or death, while the overall survival (OS) is the duration from the start of 
treatment till death. With a median follow up of 22.4 months, the 36 months OS was 
89.8% ± 10.2 and 85.4 ± 13.5 for patients with and without thrombosis respectively, 
while the EFS was 86.7% ± 10.3 and 81.7 ± 13.3 for patients with and without 
thrombosis respectively. There was no significant difference in the OS (P = 0.91) and 
EFS (P =0.85) when comparing patients with and without thrombosis (Figure 9 and 
10). 
Table 6: Symptoms and comorbidities in the studied pediatric ALL thrombus 
patients  
Symptom or complication Frequency (%) 
Symptoms *  
Headache 39/75 (52%) 
Convulsions 16/75 (21.3%) 
Vomiting 6/75 (8%) 
Blurred vision 6/75 (8%) 
laryngeal paralysis 1/75 (1.3%) 
Swelling &pain 7/75 (9.3%) 
Comorbidity 
No 
Yes 
 
57 (90.5%) 
6 (9.5 %) 
Hemiplegia 3 (4.8%) 
Hypotonia 1 (1.6%) 
Tremors 1 (1.6%) 
Unstable convulsions 1 (1.6%) 
*Most of patients had more than 1 clinical symptom associated with the incident, where 53 
patients had 75 symptom associated with the thrombosis. No data for 10 patients regarding 
symptoms associated with event.  
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Figure 9: Overall survival (OS) of the thrombosis group compared to non-
thrombotic group. The 3 years OS for the non-thrombus and thrombus patients was 85.4 
± 13.5 and 89.8% ± 10.2, respectively. No significant difference in OS between the 2 groups 
(P = 0.91). 
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Figure 10: Event free survival (EFS) of the thrombosis group compared with 
the non-thrombotic group. The 3 years EFS for the non-thrombus and thrombus patients 
was 81.7 ± 13.3 and 86.7% ± 10.3, respectively. No significant difference in EFS between 
the 2 groups (P =0.85). 
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3.7 Site of thrombosis 
Most of the patients had more than 1 clot at different sites. A total of 79 clots 
were diagnosed in the 63 patients with thrombosis. The most common sites of 
thrombosis were central nervous system (CNS) (n=55), upper venous system (n=17) 
and lower limb (n=7). Patients with a CNS site of thrombosis had either a cerebral 
venous sinus thrombosis or infarction. On the other hand, those with an upper 
venous system site of thrombosis had the clot in either the internal jugular vein 
and/or the superior vena cava (Table 7). 
Table 7: Site of thrombus in 63 pediatric ALL patients 
Site of VTE Thrombosis sites 
N=79* 
CNS  
 
Sinus venous thrombosis 
Thrombosis with infarction  
55 (69.6%) 
 
50 (63.3%) 
5   (6.3%) 
 
Upper venous system: 
 
Internal jugular vein 
Superior Vena Cava 
 
             17 (21.4%) 
 
16 (20.2%) 
1   (1.2%) 
Lower limb 7 (8.8%) 
Total 79 (100%) 
    *79 clots were diagnosed in 63 patients  
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3.8 MTHFR C677T Genotyping 
Presence of a C677T mutation creates a new restriction site for HinfI in the 
amplified MTHFR PCR product resulting in 2 fragments (175 bp, 23 bp). On the 
other hand, its absence results in the PCR product remaining intact (198 bp). The 
digestion of the PCR product showed production of 198 bp in CC wild type. 
Heterozygous allele produced 3 bands: 198, 175 and 23 bp. Homozygous allele 
produced 2 bands: 175 bp, 23bp (Figure 11). Our results showed that, in the case 
group 22/63 patients (34.9 %) were wild type allele, 36/63 patients (57.1%) were 
heterozygous allele and 5/63 patients (7.9 %) were homozygous allele (Table 8). On 
the other hand, in the control group 39/63 patients (61.9%) were wild type allele, 
18/63 patients (28.6 %) were heterozygous allele and 6/63 patients (9.5 %) were 
homozygous allele. There was a significant difference between patients with and 
without thrombosis (P=0.002) with odds ratio 3.028 and 95% confidence interval 
(CI) (1.465-6.258). 
 
Figure 11:  MTHFR PCR product digestion using HinfI Fast digest enzyme on 
15 % acrylamide gel. Patients can either be wild type (one band; 198 bp) (lane 4-9), 
heterozygous (3 bands; 198, 175, 23) (lane 10) or homozygous C677T (2 bands; 175, 23 bp) 
(lane 3), in addition the 23 bp band not detected on the gel. 
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3.9 FV Leiden Genotyping 
Presence of a FV mutation abolishes a restriction site for MnII enzyme in the 
amplified FV PCR product resulting in 2 fragments (157 bp, 130 bp).  On the other 
hand, its absence results in 3 fragments (157, 93 and 37 bp). The PCR product 
digestion showed production of 157, 93 and 37 bp bands in case of wild type. In case 
of heterozygous alleles 157, 130, 93 and 37 bp bands were produced, while 
homozygous allele showed 157 and 130 bp bands as shown in figure 12. Our results 
showed that in thrombus patients, 52/63 patients (82.5 %) were wild type allele, 
10/63 patients (15.9%) were Heterozygous allele and 1/63 (1.6 %) was homozygous 
allele. On the other hand, in the control group 53/63 patients (84.1%) were wild type 
allele, 9/63 patients (14.3 %) were heterozygous allele and 1/63 patient (1.6%) was 
homozygous allele. Comparing the 2 groups showed no significance difference   (P 
= 0.811) (Table 8). 
 
Figure 12: FV Leiden PCR product digestion using MnII Fast digest enzyme on 
15 % acrylamide gel. Patients can either be wild type (3 bands; 157, 93 and 37 bp) (lane 
2-5&7), homozygous (2 bands; 157 and 130 bp) (not shown in this figure) or heterozygous 
(4 bands; 157, 130, 93 and 37 bp) (lane 1, 6). 
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3.10 Prothrombin G20210A Genotyping 
The expected produced bands in case of wild type allele G/G will be 219 bp 
in M lane while in N lane will has 219 bp and 340 bp in N lane, the Homozygous 
A/A allele will produce 219 bp and 340 bp in M lane and 219 bp band in N lane, 
while the heterozygous allele G/A will produce 219 and 340 in both lanes (Figure 
13). Our results showed that out of the 63 patients with thrombus 61 patients (96.8 
%) were wild type allele, 2 patients (3.2%) were heterozygous allele and there was 
no homozygous allele detected. On the other hand, in the control group 61 patients 
(96.8 %) were wild type allele, 2 patients (3.2 %) were heterozygous allele and there 
was no homozygous allele detected. There was no significant difference detected 
between patients from both groups (Table 8). 
 
Figure 13: Prothrombin G20210A allele specific PCR products on agarose 2% 
gel. Each patient had 2 adjacent lanes (M and N). The M lane represents the PCR product 
containing the Mutant allele primer, while N lane represents the PCR product containing the 
wild type allele primer. Wild Type allele (lane 2, 3, 5, 6) showed 340 and 219 bp bands in 
the N lane while 219 Bp band only produced in the M lane. The heterozygous allele (lane4) 
showed 340 and 219 bp bands in both lanes N and M.  
 
 43 
 
3.11 Combined Genes 
Having more than one mutation didn’t show a significant effect on 
increasing the risk of thrombus incidence (p= 0.087) Table 8. 
Table 8: Shows the prevalence of the studied genes among patients in the case 
and control groups. 
 Cases 
N (%) 
Control 
N (%) 
P Value  OR (CI 95 %) 
Factor V Leiden 
Wild 
Mutant;  
Heterozygous  
Homozygous  
 
52 (82.5%) 
11 (17.5%) 
10/63 (15.9%) 
1/63   (1.6%) 
 
53 (84.1%) 
10 (15.9 %) 
9/63   (14.3%) 
1/63 (1.6%) 
0.811  
 
1.121   
(0.439 -2.86) 
MTHFR C677T 
Wild 
Mutant: 
Heterozygous  
Homozygous 
 
22/63 (34.9 %) 
41/63 (65 %) 
36 /63 (57.1%) 
 5/63   (7.9 %) 
 
39/63 (61.9 %) 
24/63 (38.1 %) 
18/63 (28.6 %) 
 6/63   (9.5 %) 
0.002 
 
 
 
 
3.028  
 
(1.465-6.258) 
 
 
 
 
PT G20210A 
 Wild 
Mutant: 
Heterozygous  
          Homozygous 
 
61/63 (96.8 %) 
2/63    (3.2 %) 
2/63    (3.2 %) 
0 
 
61/63 (96.8 %) 
2/63   (3.2 %) 
2/63    (3.2 %) 
0 
* 
   * 
 
Combined genes  
(Multiple traits) 
 
 
No mutation 
Single mutation 
2 mutation 
 
 
 
 
 
17/63 (27%) 
38/63 (60.3% ) 
 8/63 (12.7%) 
 
 
 
 
32/63 (50.8%) 
26/63 (41.3%) 
5/63   (7.9% ) 
 
0.087 
 
 
         3.12  
(0.852-10.647) 
 
* No p value because of small number of cases within sub groups.  
. 
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4. Discussion 
The thrombus risk in ALL patients is thought to arise from idiopathic 
generation of thrombin at diagnosis associated with decrease in the inhibitory effect 
of anti-thrombin due to depletion by asparaginase in addition to other risk factors 
(Payne & Vora, 2007). In this study, we examined 63 ALL pediatric patients with 
thrombosis and 63 matched non thrombus patients. Our main objective was to 
identify the main risk factors for thrombosis in Egyptian pediatric ALL patients. Up 
to our knowledge there were no reports about the risk factors for thrombosis in this 
population of patients. Since the genetic factors mainly depend on ethnicity so it is 
important to study those risk factors in Egyptian population in addition to the clinical 
factors.  
4.1 Patients Gender, Age, IPT and Risk Stratification as 
Risk Factors for Thrombosis  
The current study showed that the thrombosis incidence was higher in SR and 
HR patients than LR patients. Out of the 63 patients with thrombosis, 81% were 
SR/HR while 19% were LR. These results are consistent with other investigators 
reports, in a study conducted on patients treated with Total XV study protocol 
thrombosis incidence was reported to be higher in SR and HR patients. Out of 36 
patients with thrombosis 86% of the patients were standard and high risk while 
13.8% of the patients were low risk (Pui et al., 2009). In addition, It was reported that 
the frequency of SR/HR  patients among pediatric ALL patients  in Egypt was 57.4% 
(Sidhom et al., 2013). There was a higher frequency of SR/HR patients in the current 
study thrombus patients when compared to what was reported by Sidhom et al 2013. 
This higher frequency can implicate the importance of considering the Risk 
stratification as a risk factor for thrombosis incidence. 
In addition, it was found in the current study that patients greater than 10 
years old had a higher incidence of thrombosis. Where the percentage of patients 
with age greater than 10 and less than or equal 18 was 52.4%, while the percentage of 
patients from 1 year to less than 5 years and from 5 years to less than 10 years was 
found to be 17.5% and 30.2% respectively (Table 1). Similarly, it was reported that 
age group greater than 10 years was associated with higher risk of thrombus in Total 
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XV study protocol ( Pui et al., 2009). The same results were reported by Dana-Farber 
cancer institute protocols results from 1991 to 2008 (Grace et al., 2011). This was 
explained by the delayed dexamethasone clearance in older patients. In addition, it 
had been shown that older pediatric ALL patients have both decreased fibrinolysis 
and decreased anticoagulant factors when compared to younger patients receiving the 
same therapy (Appel et al., 2008; Pui et al., 2009; Yang et al., 2008). On the other 
hand, it was reported that the percentage of Egyptian pediatric ALL patients with age 
greater than 10 years was 25% (Sidhom et al., 2013). This difference in patients’ age 
distribution between the current study thrombus patients and what was reported by 
Sidhom et.al 2013 indicates that there may be an important role for age as an 
important risk factor for thrombosis.  
The patients gender was analyzed in the current study thrombus group, the 
males’ frequency in the thrombus group were 70% while 30% were females. These 
results are consistent with what was reported before regarding male predominance in 
acquiring thrombosis in ALL patients (Pui et al., 1985). On the other hand, Sidhom 
et al. 2013 reported male frequency was 60% while female was 40% in pediatric 
ALL patients. The current study showed a slight higher frequency of males in the 
thrombus patients when compared to what was reported by Sidhom et.al 2013. This 
indicates that males may have higher risk for thrombosis. 
The immunophenotyping results of the current study thrombus patients 
showed 68.3% of the patients were B cell and 31.7% T cell precursor. This is 
consistent with what was reported regarding a higher frequency of T cell precursor 
in the thrombus ALL patients in comparison with those without thrombosis (26% vs. 
10%) (Grace et al., 2011). On the other hand, Sidhom et al. 2013 reported 75.8% of 
the studied patients were B cell precursor while 24.2% were T cell precursor. This 
slight increase in T cell frequency in thrombus patients may indicate it as risk factor 
for thrombosis. 
Based on what we demonstrated in this study, it is clear that both the age 
greater than 10 years and SR/HR patients have a significant higher risk of thrombus 
incidence more than others. While both males and T cell patients have a slight higher 
risk than the other patients.  
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4.2 Number of L-Asparaginase Doses Given Before 
Thrombosis 
In the current study, patients were divided into 3 groups according to the 
number of L - Asparaginase doses received before the thrombosis incidence. The 
number of patients who had thrombus after receiving 5 to 9 L - Asparaginase doses 
(41.2%) was higher than the other 2 groups. This may have an implication of 
increase thrombosis risk after the 5
th
 to the 9
th
 dose of L - Asparaginase due to the 
accumulation of doses till the end of the induction phase which contains 6 or 9 doses 
of L - Asparaginase according to the disease risk. In addition to the number of 
accumulated asparaginase in induction phase, there are other thrombosis risk factors 
as the prednisolone glucocorticoids and the hyper-coagulopathy associated with the 
disease. On the other hand, the patients who received L - Asparaginase greater than 9 
doses have dexamethasone glucocorticoid administrated concomitantly which is 
characterized by less risk of inducing thrombosis than prednisolone. Furthermore, 
the hyper-coagulopathy state of the patient from the disease becomes lower than in 
the induction phase (Nowak-Göttl et al., 2003). 
4.3 Time of Thrombus Incidence as a Risk Factor for 
Thrombosis  
The current study results showed that 66.3% of the thrombosis incidence took 
place in induction phase while 33.3% of the patients had the thrombosis in 
continuation phase. Similarly, other investigators reported that the majority of 
thrombosis incidents took place in the induction phase of the treatment protocol 
(Payne & Vora, 2007). In a retrospective study, it was reported that 90% of the 
thrombosis incidence in ALL patients treated on BFM-90 German protocol occurred 
during the induction phase.  
The higher incidence of thrombosis during the induction phase in comparison 
with the rest of treatment phases was explained by different factors, where the 
disease is still highly active with high thrombin production and a high burden of 
lymphoblast cytolysis. In addition, the treatment is highly intense during induction 
containing a combination of concurrent administration of glucocorticoids and L-
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asparaginase (Sutor et al.,1999). On the other hand, patients in the  post induction 
phases have less cell lysis and treatment intensity (Caruso et al., 2006). Another 
reason for high incidence of thrombosis in induction is the type of treatment used in 
the protocol. Total XV treatment protocol used in this study is applying prednisolone 
glucocorticoids in the induction phase. It was reported in a study comparing 2 BFM 
studies that the risk of thrombosis during induction was much higher with 
prednisolone than dexamethasone (thrombosis frequency in BFM90/95 prednisolone 
=10.4% while BFM 2000 dexamethasone =1.8 % p=0.028) and this is consistent 
with the current study results (Nowak-Göttl et al., 2003). This higher incidence of 
thrombosis in induction phase indicates the importance of considering patients in 
induction phase at higher risk of thrombosis than others. 
4.4 Rechallenge with L – Asparaginase After Thrombus 
Incidence 
In the current study, 88.9% of the patients with thrombus were rechallenged 
with L – Asparaginase, out of those patients 28.3% were progressed. Grace et al. 2011 
confirmed that L -Asparaginase can be rechallenged in cancer patients with 
thrombosis. The rechallenging of thrombus patients with L - Asparaginase might be 
needed to achieve high EFS and OS in these patients. In DFCI protocols (1991-2008), 
Grace et al. 2011 reported that out of the 27 pediatric patients who got thrombus 74% 
of patients were rechallenged. The progression on rechallenge was 20% of the 
rechallenged patients in that study and this is comparable with what was demonstrated 
by our study. The guidelines used by Grace et al. 2011 to rechallenge patients with L-
Asparaginase were to closely monitor anti-FXa levels and imaging should 
demonstrate thrombus improvement or stabilization before rechallenging. In addition, 
he recommended 4 weeks from incidence before rechallenging patients with the L-
Asparaginase. He reported median of 9 weeks from incidence before rechallenging 
patients with the L-Asparaginase for pediatrics and 4 weeks for adults in DFCI 
protocols.
 
While in the current study, the median duration from thrombus till 
rechallenge was 10 weeks that is comparable with DFCI protocols results. It is 
important to mention that the thrombus patients in the current study was rechallenged 
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with L-Asparaginase once the thrombus is stationary or showed partial recanalization 
in order to achieve the best patients’ outcome. 
4.5 Prognosis and Outcome of Patients with Thrombosis in 
Comparison to Control Patients 
In the current study, there was no significant difference between EFS (P 
=0.856) or OS (P= 0.912) of the thrombus patients and those patients in the control 
group. This comparable EFS and OS between the 2 groups may be explained by the 
high percentage of rechallenged patients (88.9%) in the current study, which means 
less number of missed L - Asparaginase doses and better adherence to the treatment 
protocol. In addition, a study was done by Grace et al. 2011 presenting the results of 
Dana-Farber protocols from 1991 to 2008 showed that the thrombus history didn’t 
affect the patient prognosis. In his study, the EFS and OS rates in patients with 
thrombus were similar to those in patients treated with the same treatment protocol 
but without thrombus. This was explained by the guidelines followed to rechallenge 
asparaginase and avoid asparaginase discontinuation which negatively affect the EFS 
and OS. On the other hand, it has been reported that thrombus patients had a lower 
EFS than those patients treated with the same protocol and did not have thrombosis. 
This was explained by early asparaginase discontinuation (Hunault-Berger et al., 
2008; Ku et al., 2009). Based on the similar OS and EFS rates in patients from the 
thrombus and the non-thrombus group of the current study, we can conclude that 
following a strict guidelines in resuming L- Asparaginase after thrombosis incidence 
is very important for enhancing thrombus patients survival. 
4.6 Site of Thrombosis 
It was found in the current study that the most common thrombus site was the 
cerebral sinuses (69.6%) followed by upper venous system (21.4%) while the CVL 
use did not have an effect on the thrombus formation in the current study. Similarly, 
it was reported that cerebral venous sinus thrombosis has high prevalence in ALL 
pediatric patients followed by upper venous system thrombosis and lower limb 
(Payne & Vora, 2007). A review done on symptomatic thrombosis in pediatric ALL 
between 1966 and 2003 reported that 50% of the incidence was CNS and 50% non-
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CNS (Athale & Chan, 2003a). In addition, a meta-analysis done on 17 studies having 
1752 pediatric ALL patients reported that out of 91 events 53.8% were in CNS 
(Caruso et al., 2006). However, it was reported in the results of DFCI that the most 
common site is the upper limb and the CVL associated thrombus followed by the 
sinus venous thrombus and lower limb (Grace et al., 2011). This difference in results 
between the current study and the DFCI results can be explained by our limited use 
of CVL when compared to the other institution in ALL patients. 
4.7 Comorbidities and Symptoms Associated with 
Thrombosis in ALL Patients 
The present study showed that the most common clinical symptoms 
associated with sinus thrombus were headache (52%), convulsions (21.3%). On the 
other hand, the lower limb DVT presented commonly with pain and swelling (9.3%). 
These symptoms are similar to those described in previous studies (Grace et al., 
2011; Payne & Vora, 2007).
 
Comorbidity is a long lasting complication associated with the patient, in the 
current study it is associated with the patients due to thrombosis. We found in the 
current study that 10.7% of patients with CNS thrombosis suffered from 
comorbidities in the form of hemiplegia, long lasting tremors, unstable convulsions 
and hypotonicity. Usually the comorbidity of thrombosis is associated with CNS 
thromboembolism. It was reported that 15–20% of  patients with CNS thrombosis are 
associated with comorbidities which appear in the form of hemiparesis, aphasia or 
having residual neurological deficits (Athale & Chan, 2003a). It is important to 
notice that comorbidities associated with thrombosis did not affect the patients’ 
treatment plan only but also it affects the patients’ quality of life as it causes long 
term complications to the patients. 
 
4.8  Inherited Thrombophilia as a Risk Factor for 
Thrombosis 
The inherited thrombophilia role as risk for thrombosis in cancer patients is 
controversial. There are studies that reported no association between the FV Leiden, 
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Prothrombin G20210A and MTHFR C677T and risk of thrombosis, while others 
reported an association between those mutations and thrombosis incidence in cancer 
patients. The variability in association of those mutations to thrombosis risk factors 
was a great motivation to start the current study in Egyptian pediatric ALL patients. 
4.8.1 FV Leiden and PT G20210A 
The current study was a case control one and it was done on 2 groups of 
Egyptian pediatric ALL patients. Each group had 63 patients matched in sex, disease 
risk and age group. The results showed that the prevalence of FV Leiden mutation in 
thrombus group was 17.5 % while it was 15.9 % in the control group. There was no 
significant difference between both groups in FV Leiden mutation P value = 0.81. 
The prothrombin G20210A mutation prevalence in the current study showed no 
significant difference between the 2 groups. The 2 groups almost have the same PT 
G20210A prevalence which was 3.2 %. No homozygous allele was detected for PT 
G20210A only heterozygous. These results are consistent with other investigators 
findings, where a study done to evaluate the VTE risk on gynecologic oncology 
patients concluded that FV Leiden is not a risk factor for VTE incidence (Ravin et 
al., 2002). Another study done on 135 Turkish pediatric leukemia patients showed 
that 10.3% of the patients had FV Leiden mutation while 5% had prothrombin 
G20210A mutation. Out of the 135 patients 3 had thrombosis and none of the 3 
patients had FV or prothrombin mutation. This study suggested that there is no 
association between FV and Prothrombin G20210A mutation and risk of thrombosis 
in leukemia pediatric patients (Akın et al., 2012). In addition, a prospective study 
done on 211 cancer patients in Brazil, patients were divided into 2 groups with and 
without thrombosis to investigate the role of FV Leiden and PT G20210A in 
thrombosis risk. FV Leiden was found with a frequency of 2.7% and 1.5% in the 
control and thrombus group respectively. Prothrombin G20210A was found in 1.3% 
and1.5% of control group and the thrombus group respectively. This study concluded 
that FV Leiden and PT G20210A don’t have a significant role in the risk of 
thrombosis in patients with different types of cancer (Ramacciotti et al., 2003). 
Finally, a prospective cohort study done by PARKAA  group on ALL pediatric  
 51 
 
patients suggested that there was no correlation between the FV Leiden or 
prothrombin G20210A and the risk of thrombosis (Mitchell et al., 2003).  
In contrast to the previous studies, other studies showed that FV Leiden, 
Prothrombin G20210A mutations have an important role in increasing the risk of 
thrombus in cancer patients. As example, a study done on cancer patients showed 
that PT G20210A was a significant risk factor of VTE (Kennedy et al., 2005). 
Another study was done on 80 ALL pediatric patients reported the presence of FV 
Leiden and prothrombin 16.3% and 4% respectively in patients without thrombosis. 
While 50% of the patients with thrombosis had Prothrombin G20210A mutation 
(Harlev et al., 2010). In a prospective study, researchers showed that there was a 
significant thrombosis risk associated with inherited thrombophilia traits in pediatric 
ALL patients. This prospective study was done on 289 ALL patients. It was found 
that 58/289 patients were associated with inherited thrombophilia trait. While 27 out 
of the 58 patients (46.5%) with at least 1 inherited thrombophilia trait developed 
thrombosis compared to 5/231 (2.2%) patients without inherited thrombophilia trait 
(Nowak-Göttl et al., 1999). 
4.8.2 MTHFR C677T  
In the current study, MTHFR C677T mutation prevalence was found to be 
highly significant in the thrombus group when compared to the control group with    
P value = 0.002. The prevalence of MTHFR C677T mutation in the thrombus group 
was 65.1% vs. 38.1% in the control group. The results showed that the presence of 
MTHFR C677T mutation in ALL pediatric patients increases the risk of having 
thrombosis by 3 folds (Table 8). These findings presented here confirm other studies 
which reported the increase of thrombosis risk in patients with MTHFR C677T 
mutation. 
In agreement with our results, it was reported that MTHFR C677T mutation 
is a risk factor for thrombosis in Indian patients (Kumari et al., 2014). In a case 
control study done in Japan, it was found that MTHFR gene mutation was an 
important risk factor for thrombosis when combined with other prothrombotic defect 
(Fujimura et al., 2000). In Russia, it was reported that MTHFR C677T mutation was 
 52 
 
a risk factor for pulmonary artery thromboembolism (Avdonin et al., 2006). A study 
done on 298 Chinese patients diagnosed with: deep venous thrombosis (DVT), 
cerebral haemorrhage and cerebral infarction and coronary artery disease (CAD) 
reported that MTHFR C677T mutation was an important risk factor for DVT and 
cerebral infarction while the CAD was less associated with the mutation (Zheng et 
al., 2000). Another study done on Chinese patients also reported that the MTHFR 
C677T mutation was a risk factor for DVT (Guo et al., 2002). A meta-analysis 
included 24 studies with 4048 controls and 2339 patients with thrombosis reported 
that MTHFR C677T polymorphism was a risk factor for thrombosis in Chinese 
population (Zhang et al., 2014). However, it was reported by Ramacciotti et al. 2003 
that MTHFR C677T is not a significant risk factor for thrombosis. Where MTHFR 
677T was found in 60.5% and 53.1% of control group and thrombus group 
respectively. The 2 groups of patients were comparable to each other. Another study 
done on Chinese patients reported the same results (Lu et al., 2002). In a case control 
study done on Brazilian patients it was reported that the presence of MTHFR C677T 
mutation was not a significant risk factor for thrombosis (Morelli et al., 2002) 
Based on what was demonstrated in the current study, it is clear that MTHFR C677T 
is an important risk factor for thrombosis in Egyptian pediatric ALL patients while 
FV Leiden and PT G20210A are not. 
4.9 Multiple prothrombotic Defects vs. Single and Risk of 
Thrombosis 
Our study showed that having more than one mutation didn’t have a 
significant effect on thrombus incidence. This may be due to the small sample size of 
the study group (63 patients) and studying 3 prothrombotic risk factors only. In 
contrast to our results a German study showed a higher risk for thrombosis in 
patients had more than 1 prothrombotic defect. The German study was done on 289 
pediatric ALL patients treated on Berlin-Frankfurt-Munster (BFM) 90/95 protocol to 
assess the risk of thrombosis in patients having prothrombotic defects (Nowak-Göttl 
et al., 1999). This can be due to the large number of prothrombotic defects studied by 
the German than in our study. In addition to FV Leiden, MTHFR C677T, 
prothrombin G20210A mutations, they also studied the lipoprotein (a) concentration, 
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deficiencies of anti-thrombin, protein S and protein C. The possibility to have 
significant prothrombotic defects associated with risk of thrombosis will be higher in 
case of studying larger number of parameters for each patient. 
4.10 Prevalence of Inherited thrombophilia in Egyptian 
Pediatric ALL patients 
4.10.1 FV Leiden and PT G20210A prevalence in Egyptian Pediatric 
ALL patients 
The current study showed that FV Leiden prevalence in the control patients 
was 14.3% and 1.6% for heterozygous and homozygous alleles respectively, while in 
the thrombus patients was 15.9% and 1.6% for heterozygous and homozygous alleles 
respectively. There was no significant difference in FV Leiden prevalence between 
the patients with and without thrombosis. On the other hand, the PT G20210A 
prevalence in the control patients and the thrombus patients was the same (3.2%) for 
heterozygous and no homozygous was detected in both groups. To the best of our 
knowledge, this is the 1
st
 study on the prevalence of FV Leiden and prothrombin 
G20210A in Egyptian pediatric ALL patients.  
          Association between ALL risk and FV Leiden and PT G20210A 
mutation 
The prevelance of FV leiden and PT G20210A mutation in our control 
patients was comparable to the healthy Egyptian population. It was reported that the 
prevelance of  FV leiden and prothrombin G20210A mutations in healthy Egyptian 
population was 16.5% and 1% respectively (Ulu et al., 2006), while ours was 15.9 % 
and 3.2 % respectively. These results indicate that those 2 mutations could not be 
associated with ALL risk. On contrary, it was reported in Iran that there was an 
association between pediatric  ALL risk and FV Leiden when compared with healthy 
population (Rahimi et al., 2012), while the prothrombin G20210A mutation was not 
a risk factor for pediatric  ALL (Rahimi et al., 2013). 
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4.10.2 MTHFR C677T point mutation in Egyptian pediatric ALL 
patients 
Our results showed that MTHFR C677T mutation prevalence in the control 
patients was 28.6% and 9.5% for heterozygous and homozygous alleles respectively, 
while in the thrombus patients was 57.1% and 7.9% for heterozygous and 
homozygous alleles respectively. Several studies were done on Egyptian pediatric 
ALL patients to assess the association between MTHFR polymorphism and several 
toxicities. A study done to assess the high dose methotrexate toxicity in relation to 
the prevalence of MTHFR C677T reported that  it was 35%, 10% for heterozygous 
and homozygous alleles, respectively (El-Khodary et al., 2012). While another study 
reported MTHFR C677T prevalence as 27.5% and 40% for heterozygous and 
homozygous alleles, respectively (Tantawy et al., 2010). There is a higher percentage 
of homozygous allele reported by Tantawy et al when compared to EL-Khodary et 
al. and the current study results. 
Association between ALL Risk and MTHFR C677T 
A previous study done on Egyptian population to evaluate the association of 
MTHFR C677T on the pediatric ALL patient, recruited 88 ALL pediatric patients 
and 311 healthy Egyptian individuals. The study reported prevalence of MTHFR 
C677T of 47.7 % and 8% for heterozygous and homozygous allele in the ALL 
patients, respectively. While the control healthy Egyptian patients showed MTHFR 
prevalence of 43.4% and 6.4% for heterozygous and homozygous alleles, 
respectively. The study concluded that MTHFR C677T polymorphism lack 
protective effect against ALL risk (Kamel et al., 2007). On the other hand, the 
present study results showed that the prevalence of MTHFR C677T in the control 
group was 28.6 % and 9.5 % for heterozygous and homozygous alleles, respectively. 
When we compare these results with the prevalence of MTHFR C677T in healthy 
Egyptian population reported in Kamel et.al 2007 study we found that the healthy 
Egyptian population had a higher incidence of MTHFR C677T than the ALL 
patients. This may indicate a protective role for MTHFR C677T mutation against 
ALL disease risk in Egyptian population. The current study results are in line with 
other studies done on the MTHFR and its role in ALL risk. They suggested that 
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increase in the MTHFR variants is associated with decreased risk of ALL, which 
means that MTHFR variants had a protective role against ALL (Skibola et al., 1999; 
Tone et al., 2001)
 
. 
A meta-analysis included 12 articles with 4146 controls and 1803 pediatric 
ALL patients reported that MTHFR C677T mutation TT genotype had a protective 
role against ALL in the Chinese children (Lin et al., 2014). Another meta-analysis 
included 11 articles with 2,438 controls and 1,738 ALL patients found that MTHFR 
polymorphism had a protective role from ALL (Xiao et al., 2014). In Brazil, a study 
done on pediatric ALL patients found that MTHFR C677T polymorphism was 
associated with a lower risk of ALL risk
 
(Tone et al., 2001). The MTHFR 
polymorphism protective role against ALL was explained by the following 
mechanism. Leukemia arises commonly as a result of DNA deletions, inversions and 
translocations in the genes responsible for the regulation of homeostasis or blood cell 
development. It was reported that Folate deficiency is associated with mis-
incorporation of Uracil into DNA. During uracil excision repair DNA double strand 
breaks and lead to increase of chromosomal aberrations risk. These breaks could 
contribute in increasing cancer susceptibility (Robien et al., 2003).  
Normally, MTHFR enzyme directs 5, 10-methylenetetrahydrofolate towards 
the synthesis of methionine at the expenses of DNA synthesis. Methylene- THF is a 
methyl donor, which converts deoxyuracil monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP) in the presence of thymidylate synthase 
enzyme. Increase of 5, 10 - methylene - THF plasma levels, leads to increasing of 
dUMP conversion to dTMP. Which means a reduction in uracil mis incorporation 
rate and optimal DNA synthesis  (Figure 5) (Robien et al., 2003). In case of MTHFR 
polymorphism, the decrease in the enzyme activity leads to decrease in the 
conversion of 5, 10-methylene- THF to 5-methyl-THF and increase homocysteine 
levels takes place. It is thought that MTHFR polymorphism can lead to optimal DNA 
synthesis and less Uracil mis incorporation. This means less chromosomal aberration 
during Uracil mis incorporation excision repair process (Robien et al., 2003). 
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5. Conclusion 
We found that MTHFR C677T is important risk factor for thrombosis in 
Egyptian pediatric ALL patients. The presence of this polymorphism can increase the 
risk of thrombosis 3 folds more than those patients who did not have the 
polymorphism. In addition, the patients who are older than 10 years, on SR/HR 
treatment protocol or in induction treatment phase are also at high risk of thrombosis 
than others who are less than 10 years, treated on LR protocol or in any treatment 
phase other than induction. Having one or more of those factors can increase the risk 
of thrombosis in pediatric ALL patients. Those factors can be used as important 
indicator for the risk of thrombosis in ALL patients. Using those factors will help in 
the prediction of the thrombosis susceptibility for ALL patients and a prophylaxis 
therapy can be given before having the thrombosis. Prediction of thrombosis is 
crucial in enhancing the patient quality of life by preventing the complications 
associated with the thrombosis that represent 10% of patients in our study. We also 
found that there was no significant role for FV Leiden and PT G20210A in risk of 
thrombosis. 
Rechallenging patients with asparaginase as soon as possible after the 
thrombus total recanalization took place is very essential as it can affect the patient 
survival. We found that the EFS and the OS of the patients were the same in the 2 
studied groups. That’s why we recommend restarting the L Asparaginase once the 
thrombus is stationary or showed partial recanalization in order to keep the EFS and 
the OS of thrombus patients as those without thrombosis. In addition, it was found 
that there was no significant association between the thrombosis risk and the 
combined mutations. Most probably this finding was due to the small sample size 
and studying 3 prothrombotic factors only. 
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6. Future recommendations 
A routine screening for MTHFR polymorphism should be done in ALL new 
patients before starting L-asparaginase and prednisolone to evaluate the risk of 
thrombosis especially for those who have other risk factors such as age greater than 
10 years or SR/HR patients. Further prospective study is recommended to evaluate 
the importance of using anticoagulant as prophylaxis therapy in ALL pediatric 
patients having high risk factors for thrombosis 
Multicenter study with larger sample size is recommended to evaluate the 
role of FV Leiden, PT G20210A as a thrombosis risk factor in Egyptian pediatric 
ALL patients. 
In the present study, we looked at genetic factors only, where other possible 
risk factors such as protein S, protein C, homocysteine, anti- thrombin levels were 
not evaluated. Evaluation of large number of factors will clarify whether the risk of 
thrombosis was affected by the presence of combined risk factors or not. 
 A large case control study is recommended to evaluate the protective role of 
MTHFR C677T against ALL. 
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